NCT06855277 2026-02-24
AcTFirst
Novartis
Phase 3 Recruiting
Clinical Trials
7 trialsNCT04876651 2026-02-20
The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3 Terminated
NCT03523338 2025-12-10
An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant Prostate Cancer
Aragon Pharmaceuticals, Inc.
No longer available
NCT05801965 2025-05-25
A Digital Therapeutic Solution for Cancer Patients
Sidekick Health
Phase NA Completed
NCT06636682 2024-10-21
FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
Cellvax Therapeutics Inc
Phase 2 Recruiting
NCT03501173 2023-07-25
GURC
Janssen Inc.
Completed
NCT04446429 2021-12-10
Anti-Androgen Treatment for COVID-19
Applied Biology, Inc.
Phase NA Completed